Company: SINT
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024040
Chunk: 39

Company: Sintx Technologies, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 2
Chunk 39
---
 business, and does not include any adjustments
to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities
that may result from uncertainty related to its ability to continue as a going concern within one year from the date of issuance of these
condensed consolidated financial statements.

For
the six months ended June 30, 2025, and 2024, the Company incurred a net loss of $4.6 million and $3.1 million, respectively, and used
cash in operating activities of $3.7 million and $4.9 million, respectively. The Company had an accumulated deficit of $286 million and
$282 million as of June 30, 2025, and December 31, 2024, respectively. We will require substantial future capital in order to continue
operating our business, conduct research and development and regulatory clearance and approval activities necessary to bring our products
to market, and to establish effective marketing and sales capabilities. Our existing capital resources are not sufficient to enable us
to fund the completion of the development and commercialization of all our product candidates.

To
date, the Company’s operations have been principally financed from proceeds from the issuance of preferred and common stock and,
to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses
and use cash in operations. The Company’s continuation as a going concern is dependent upon its ability to increase sales, decrease
expenses and raise additional funding. Whether and when the Company can attain profitability and positive cash flows from operations
or obtain additional financing is uncertain.

We
are actively seeking opportunities to raise additional equity and/or debt financing. However, such funding is not guaranteed and may
not be available to the Company on favorable or acceptable terms and may involve significant restrictive covenants. Any additional equity
financing, if available to the Company, will most likely be dilutive to its current stockholders. If the Company is not able to obtain
additional debt or equity financing on a timely basis, the impact on the Company will be material and adverse.

The
Board of Directors, together with management, is performing an ongoing evaluation of the Company’s business strategy and focus.

The Company’s strategic emphasis is focused on utilizing its technology in making advancements in the biomedical sector. Historically
engaged in both industrial and biomedical applications, SINTX has prioritized the development and commercialization of innovative medical
devices, leveraging its expertise in advanced ceramics and